ArticleFrontiers in oncology2026
Case Report: Proton beam therapy - friend or foe for patients with
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Proton beam therapy is increasingly implemented for lower-grade gliomas worldwide, aiming to reduce radiation exposure to healthy tissue and lower treatment related toxicity. However, robust clinical evidence of the benefit of radiotherapy delivered with protons compared to photons is lacking. Importantly, although proton therapy offers potential benefits compared to photon radiotherapy, it is still ionizing radiation and can be associated with severe complications. Emerging concerns include a possible increase of radiotherapy-induced contrast-enhancing lesions. Case presentation: A healthy woman in her mid-forties underwent a subtotal resection for an Conclusion: This case highlights that although proton beam therapy is considered safe and potentially encumbered with fewer side effects than photon radiotherapy, serious complications may occur. Careful consideration of timing and execution of adjuvant therapy for lower-grade gliomas is essential. Randomized controlled trials are necessary to disclose if proton beam therapy is beneficial or not in lower-grade gliomas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.